. 2022 Apr 1;4(5):100460. doi: 10.1016/j.xkme.2022.100460

Table 3.

Baseline Characteristics and Outcomes Measured by Study and β-Blocker Dialyzability Cohort

Characteristics and Outcomes	Highly Dialyzable β-Blocker Cohort					Poorly Dialyzable β-Blocker Cohort
	Assimon et al⁷	Weir et al¹⁰	Shireman et al⁶		Wu et al⁸	Assimon et al⁷	Weir et al¹⁰	Shireman et al⁶		Wu et al⁸
	Assimon et al⁷	Weir et al¹⁰	ACM Model	CVMM Model	Wu et al⁸	Assimon et al⁷	Weir et al¹⁰	ACM Model	CVMM Model	Wu et al⁸
Medications included in cohorts	Metoprolol Succinate, Metoprolol Tartrate	Acebutolol, Atenolol, and Metoprolol tartrate	Atenolol and Metoprolol	Atenolol and Metoprolol	Atenolol, Acebutolol, Metoprolol, and Bisoprolol	Carvedilol	Propranolol and Bisoprolol	Carvedilol and Labetalol	Carvedilol and Labetalol	Betaxolol, Carvedilol, and Propranolol
Population/ no. of cases (n = X)	17,521	3,294	3,781	3,495 (100 %)	10,446	9,533	3,294	1,157	1,042 (100 %)	10,353
Age, y	59.5	75.6	60.4	60.1 (15.2%)	55.9	59.8	75.7	58.3	57.6 (16.0%)	57.2
Females, n (%)	8,183	1,617	2,172	1,992 (57.0 %)	2,380	4,444	1,617	625	559 (53.7 %)	513
End of follow-up, d	365	180	50% mortality reached at 1,083 d	50% CVMM reached at 599 d	730	365	180	50% mortality reached at 894 d	50% CVMM reached at 481 d	730
Average follow-up, d	285	Median duration of continuous use: 471	50% mortality reached at 1,083 d	50% CVMM reached at 599 d	602	276	Median duration of continuous use: 508	50% mortality reached at 894 d	50% CVMM reached at 481 d	544
Outcomes measured	1-13, 20	2, 12, 18	1	2, 4-7, 12, 14-17	2, 12, 19	1-13	2, 12, 18	1	2, 4-7, 12, 14-17	2, 12, 19

Note: Baseline and outcomes data for each of the 4 studies, organized by β-blocker dialyzability cohort. For average follow-up time, the median duration of continuous use in the study by Weir et al¹⁰ describes the median number of days participants continuously took their assigned β-blocker. Shireman et al⁶ provided average follow-up data in terms of when 50% of their study population in each dialyzability group had experienced the outcomes of interest. The following numbers were used to code for the outcomes measured: 1, all-cause mortality; 2, acute myocardial infarction; 3, pericarditis (including cardiac tamponade); 4, atherosclerotic heart disease; 5, cardiomyopathy; 6, cardiac arrhythmia; 7, cardiac arrest (cause unknown); 8, valvular heart disease; 9, pulmonary edema due to exogenous fluid; 10, congestive heart failure; 11, pulmonary embolism and cerebrovascular accident (including intracranial hemorrhage); 12, heart failure; 13, atrial fibrillation; 14, ischemic heart disease; 15, revascularization; 16, cerebrovascular accident; 17, peripheral vascular disease; 18, ventricular arrhythmia; 19, ischemic stroke; and 20, intradialytic hypotension (≥20 mm Hg systolic blood pressure drop plus intradialytic saline administration).

Abbreviations: ACM, all-cause mortality; CVMM, cardiovascular morbidity and mortality.